176 related articles for article (PubMed ID: 37637431)
1. Cost-effectiveness analysis of selexipag for the combined treatment of pulmonary arterial hypertension.
Dong W; Zhang Z; Chu M; Gu P; Hu M; Liu L; Huang J; Zhang R
Front Pharmacol; 2023; 14():1122866. PubMed ID: 37637431
[No Abstract] [Full Text] [Related]
2. Cost-Effectiveness Analysis of Macitentan in Comparison With Bosentan in the Treatment of Pulmonary Arterial Hypertension in Iran.
Ekhlasi M; Sheikhi S; Majd ZK; Peiravian F; Yousefi N
Value Health Reg Issues; 2023 Mar; 34():78-85. PubMed ID: 36599206
[TBL] [Abstract][Full Text] [Related]
3. Randomized Trial of Macitentan/Tadalafil Single-Tablet Combination Therapy for Pulmonary Arterial Hypertension.
Grünig E; Jansa P; Fan F; Hauser JA; Pannaux M; Morganti A; Rofael H; Chin KM
J Am Coll Cardiol; 2024 Jan; 83(4):473-484. PubMed ID: 38267108
[TBL] [Abstract][Full Text] [Related]
4. Cost-utility analysis of Macitentan Vs. Bosentan in pulmonary atrial hypertension.
Nosrati M; Shahmirzadi NA; Afzali M; Zaboli P; Rouhani H; Hamedifar H; Hajimiri M
J Family Med Prim Care; 2020 Jul; 9(7):3634-3638. PubMed ID: 33102342
[TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of endothelin receptor antagonists combined with phosphodiesterase 5 inhibitor in the treatment of pulmonary arterial hypertension: a network meta-analysis].
Fu WH; Chen PL; Xia JL; Fu L; Shen Y; He WJ; Chen YH; Ren N; Jiang Q; Ma R; Wang T; Wang XN; Zhang NF; Liu CL
Zhonghua Jie He He Hu Xi Za Zhi; 2022 Feb; 45(2):158-170. PubMed ID: 35135085
[No Abstract] [Full Text] [Related]
6. [Pharmacoeconomic aspects of macitentan in the therapy of pulmonary arterial hypertension].
Moiseeva OM; Rudakova AV
Ter Arkh; 2017; 89(3):72-77. PubMed ID: 28378734
[TBL] [Abstract][Full Text] [Related]
7. Cost Effectiveness of First-Line Oral Therapies for Pulmonary Arterial Hypertension: A Modelling Study.
Coyle K; Coyle D; Blouin J; Lee K; Jabr MF; Tran K; Mielniczuk L; Swiston J; Innes M
Pharmacoeconomics; 2016 May; 34(5):509-20. PubMed ID: 26739957
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological counseling in hepatotoxicity induced by macitentan and selexipag: a case report.
Lattanzio M; Ferrari M; Martini S; Ceriani F; Imporzani A; Marino F; De Ponti R; Cosentino M
J Med Case Rep; 2022 Oct; 16(1):385. PubMed ID: 36258237
[TBL] [Abstract][Full Text] [Related]
9. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation.
Garside R; Pitt M; Anderson R; Rogers G; Dyer M; Mealing S; Somerville M; Price A; Stein K
Health Technol Assess; 2007 Nov; 11(45):iii-iv, ix-221. PubMed ID: 17999840
[TBL] [Abstract][Full Text] [Related]
10. Impact of different sequential triple oral combination therapies based selexipag on outcomes in pulmonary arterial hypertension.
Hu X; Yuan P; Chen J; Wang S; Zhao H; Wei Y; Fu J; Chen F; Ruan H; Zhang W; Zhou Y; Wang Q; Xu X; Feng K; Guo J; Gong S; Zhang R; Zhao Q; Wang L
Clin Cardiol; 2024 Feb; 47(2):e24245. PubMed ID: 38402556
[TBL] [Abstract][Full Text] [Related]
11. Cost-Effectiveness Analysis of Sacubitril/Valsartan for the Treatment of Heart Failure with Reduced Ejection Fraction in the United States.
Zueger PM; Kumar VM; Harrington RL; Rigoni GC; Atwood A; DiDomenico RJ; Touchette DR
Pharmacotherapy; 2018 May; 38(5):520-530. PubMed ID: 29601093
[TBL] [Abstract][Full Text] [Related]
12. Phosphodiesterase 5 Inhibitor for Pediatric Pulmonary Arterial Hypertension: A Cost-Utility Analysis.
Buendía JA; Lindarte EF; Guerrero Patiño D
Value Health Reg Issues; 2023 Jul; 36():44-50. PubMed ID: 37028260
[TBL] [Abstract][Full Text] [Related]
13. The clinical effectiveness and cost-effectiveness of cardiac resynchronisation (biventricular pacing) for heart failure: systematic review and economic model.
Fox M; Mealing S; Anderson R; Dean J; Stein K; Price A; Taylor RS
Health Technol Assess; 2007 Nov; 11(47):iii-iv, ix-248. PubMed ID: 17999842
[TBL] [Abstract][Full Text] [Related]
14. A Special Focus on Selexipag - Treatment of Pulmonary Arterial Hypertension.
Sorensen LM; Wehland M; Kruger M; Simonsen U; Nassef MZ; Infanger M; Grimm D
Curr Pharm Des; 2017; 23(34):5191-5199. PubMed ID: 28891448
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the combination of endothelin receptor antagonists (ERA) and phosphodiesterase-5 inhibitors for the treatment of pulmonary arterial hypertension (PAH) in pathologic human pulmonary arteries in an ex-vivo organ bath model.
Englert L; Stadlbauer C; Spaeth M; Hofmann HS; Schneider C; Hatz RA; Preissler G; Michel S; Golovchenko S; Ried M; Hoenicka M
Pulm Pharmacol Ther; 2021 Feb; 66():101985. PubMed ID: 33359621
[TBL] [Abstract][Full Text] [Related]
16. Effects of Dual Initial Combination Therapy With Macitentan Plus Riociguat or Macitentan Plus Selexipag on Hemodynamics in Patients With Pulmonary Arterial Hypertension (SETOUCHI-PH Study) - Protocol of a Multicenter Randomized Control Trial.
Akagi S; Dohi Y; Ishikawa K; Kubota K; Horimoto K; Yagi S; Hirata T; Yamamoto E; Ito H; Nakamura K
Circ Rep; 2021 Jan; 3(2):105-109. PubMed ID: 33693297
[No Abstract] [Full Text] [Related]
17. Comparative evaluation of costs and healthcare resource utilization of oral selexipag versus inhaled treprostinil or oral treprostinil in patients with pulmonary arterial hypertension.
Papademetriou E; Liu X; Beaudet A; Tsang Y; Potluri R; Panjabi S
J Med Econ; 2023; 26(1):644-655. PubMed ID: 37086091
[TBL] [Abstract][Full Text] [Related]
18. Selexipag-based triple combination therapy improves prognosis in Chinese pulmonary arterial hypertension patients.
Cui X; Lu W; Zhang D; Qie L; Li H; Li X; Liu H; Ji Q
Front Cardiovasc Med; 2022; 9():991586. PubMed ID: 36204579
[TBL] [Abstract][Full Text] [Related]
19. Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial.
Hoeper MM; Al-Hiti H; Benza RL; Chang SA; Corris PA; Gibbs JSR; Grünig E; Jansa P; Klinger JR; Langleben D; McLaughlin VV; Meyer GMB; Ota-Arakaki J; Peacock AJ; Pulido T; Rosenkranz S; Vizza CD; Vonk-Noordegraaf A; White RJ; Chang M; Kleinjung F; Meier C; Paraschin K; Ghofrani HA; Simonneau G;
Lancet Respir Med; 2021 Jun; 9(6):573-584. PubMed ID: 33773120
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
